Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy [Seeking Alpha]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Seeking Alpha
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-related macular degeneration patients with geographic atrophy, is in phase 3 testing with topline data expected in 2nd half of 2026. The global Geographic Atrophy market size is projected to reach $50 billion by 2032. Volodymyr Kalyniuk/iStock via Getty Images The last time I spoke about Annexon Inc. ANNX ) it was with respect to a Seeking Alpha article entitled " Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical compa
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement [Yahoo! Finance]Yahoo! Finance
- Annexon stock rises after director purchases shares [Seeking Alpha]Seeking Alpha
- Annexon (NASDAQ:ANNX) had its price target raised by analysts at Wells Fargo & Company from $14.00 to $27.00. They now have an "overweight" rating on the stock.MarketBeat
- Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million [Yahoo! Finance]Yahoo! Finance
- Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 MillionGlobeNewswire
ANNX
Earnings
- 11/10/25 - Miss
ANNX
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 11/21/25 - Form 4
- ANNX's page on the SEC website